

SAFETY DATA SHEET

Section 1: Identification	
Material	Nitazoxanide Tablets, 500 mg
Recommended use	Pharmaceutical use
Manufacturer	Annora Pharma Private Limited, Survey No. 261, Annaram Village, Gummadidala Mandal, Sangareddy, Telangana 502313, India.
Distributor	Camber Pharmaceuticals, Inc. , Piscataway, NJ 08854
Section 2: Hazard(s) Identification	
Hazard statements:	None
Precautionary statements:	Avoid breathing dust/fume/gas/mist/vapors/spray. Remove victim to fresh air. If in eyes, rinse cautiously with water and remove contact lens. Wash thoroughly after handling.
Other hazards	No information is available
Section 3: Composition/Information on Ingredients	
Ingredients	CAS
Nitazoxanide	55981-09-4
Corn Starch	9005-25-8
Sodium Starch Glycolate	9063-38-1
Pregelatinized starch	9005-25-8
Hypromellose	9004-65-3
Talc	14807-96-6
Magnesium stearate	557-04-0
Opadry AMB 80W510018 Green, IH#	NA
Polyvinyl Alcohol	9002-89-5
D&C Yellow #10 Aluminium Lake	68814-04-0
Talc	14807-96-6
Titanium Dioxide	13463-67-7
Lecithin	8002-43-5
FD&C Blue #2/Indigo Carmine Aluminium Lake	16521-38-3
Xanthan Gum	11138-66-2
FD&C Yellow #6/Sunset Yellow FCF Aluminium Lake	15790-07-5

Section 4: First-Aid Measures	
Inhalation	Not applicable.
Eye Contact	In case of contact, immediately flush with water. Remove contact lenses. Get medical attention if irritation persists.
Skin Contact	If excessive skin contact occurs, wash affected area with soap and water. Get medical attention if irritation develops or persists.
Ingestion	Seek medical attention in the event of overdose. Victim should be carefully observed and given symptomatic and supportive treatment. Gastric lavage may be appropriate soon after ingestion.
Important symptoms and effects, both acute and delayed	Abdominal pain, headache, chromaturia and nausea.
Section 5: Fire-Fighting Measures	
Suitable extinguishing media	Use extinguishing media appropriate for surrounding area.
Specific hazards arising from the chemical:	No information available.
Special protective equipment and precautions for fire-fighters	Wear self-contained breathing apparatus and protective suit to prevent contact with skin and eyes.
Section 6: Accidental Release Measures	
Personal Precautions	None for normal use.
Methods and materials for containment and cleaning up:	Collect tablets and place in appropriate containers for disposal. Avoid generating dust.
Section 7: Handling and Storage	
Handling	Avoid contact with eyes. Avoid excessive contact with skin or clothing. Wash hands thoroughly after handling.
Storage	Store the tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature].
Section 8: Exposure Controls/Personal Protection	
Exposure limits:	No information available
Engineering controls:	None required
Eye/Skin protection:	Under normal conditions, special eye and skin protection not required.
Inhalation protection:	Under normal conditions, special ventilation not required. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Specific target organ toxicity (repeated exposure):	No information available
Symptoms/injuries after inhalation:	No information available
Symptoms/injuries after eye contact:	No information available
Symptoms/injuries after ingestion:	In clinical trials, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea ($\geq 2\%$).
Section 12: Ecological Information	
Ecotoxicity:	No information available
Persistence and degradability:	No information available
Bioaccumulative potential	No information available
Mobility in soil:	No information available
Other adverse effects:	No information available
Section 13: Disposal Considerations	
Disposal container(s):	Dispose of in accordance with all applicable federal, state, and local environmental regulations.
Disposal method(s):	Handle contaminated packaging in same way as the substance itself. If not officially specified differently, non-contaminated packaging may be treated like household waste or recycled.
Special precautions:	Not applicable
Section 14: Transport Information	
UN Number:	Not applicable
UN proper shipping Name:	Not applicable
Transport hazard class(es):	Land Transport (DOT): Not classified as dangerous Air Transport (IATA): Not classified as dangerous Sea Transport (IMDG): Not classified as dangerous
Packing group number:	Not applicable
Environmental hazards:	Not applicable
Bulk transport guidance:	Not applicable
Special precautions:	Not applicable
Section 15: Regulatory Information	
No additional information to provide	

Section 16: Other Information

Issue Date: 14-04-2026

Version: 00

Further information

Revision date: NA

Revision note: NA.

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Annora Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Annora Pharma Private Limited reserves the right to revise this SDS.